Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Opus Genetics, Inc.

Market Cap 331M 289M 268M 250M 470M 31.26B 473M 3.17B 1.23B 15.39B 1.24B 1.22B 53.42B P/E 2026 *
-3.83x
P/E 2027 * -5.63x
Enterprise Value 331M 289M 268M 250M 470M 31.26B 473M 3.17B 1.23B 15.39B 1.24B 1.22B 53.42B EV / Sales 2026 *
22.5x
EV / Sales 2027 * 22.4x
Free-Float
88.94%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Opus Genetics, Inc.

1 day+0.25%
1 week+0.74%
Current month-6.65%
1 month-4.46%
3 months-11.14%
6 months+103.50%
Current year+102.49%
1 week 3.8
Extreme 3.8
4.26
1 month 3.8
Extreme 3.8
4.68
Current year 1.88
Extreme 1.88
5.81
1 year 0.9
Extreme 0.9011
5.81
3 years 0.65
Extreme 0.65
5.81
5 years 0.65
Extreme 0.65
7
10 years 0.65
Extreme 0.65
13.81
Manager TitleAgeSince
Chief Executive Officer 42 01/11/2023
Director of Finance/CFO 52 02/09/2025
President 60 22/10/2024
Director TitleAgeSince
Director/Board Member 77 01/11/2020
Chairman 56 01/12/2019
Director/Board Member 59 01/11/2020
Date Insider Type Main position Quantity % Market Cap.
05-18
The Foundation Fighting Blindness, Inc.
SellCompany -1,700,000 2.0886%
04-23Sell

Chief Operating Officer

4,697 0.0066%
04-23Sell

Chairperson

7,470 0.0105%
Change 5-day change 1-year change 3-year change Capi.($)
+0.25%+0.74%+337.02%+5.17% 331M
-1.21%-3.04%+39.94%+145.38% 980B
-2.48%-5.18%+51.52%+39.07% 550B
-2.14%-4.94%+16.71%+56.15% 382B
+0.25%-3.09%+23.00%+15.81% 316B
+0.61%-1.69%+25.42%+13.64% 272B
+0.22%-3.10%+24.25%+30.21% 268B
+4.59%+1.98%-40.02%-45.89% 199B
-1.19%-4.95%+16.56%+47.00% 182B
-1.35%-1.46%+14.59%+56.94% 154B
Average -0.25%-2.30%+50.90%+36.35% 330.27B
Weighted average by Cap. -0.78%-3.68%+27.83%+63.69%

Financials

2026 *2027 *
Net sales 14.69M 12.81M 11.86M 11.11M 20.83M 1.39B 20.95M 141M 54.55M 682M 55.15M 53.96M 2.37B 14.81M 12.91M 11.96M 11.19M 20.99M 1.4B 21.12M 142M 54.97M 688M 55.58M 54.39M 2.39B
Net income -94.53M -82.42M -76.33M -71.46M -134M -8.92B -135M -906M -351M -4.39B -355M -347M -15.24B -67.02M -58.44M -54.12M -50.66M -95.02M -6.32B -95.59M -642M -249M -3.11B -252M -246M -10.81B
Net Debt - -
Logo Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Employees
28
Date Price Change Volume
18/06/26 4.070 $ +0.25% 1,056,616
17/06/26 4.060 $ +4.10% 1,065,268
16/06/26 3.900 $ -0.38% 766,758
15/06/26 3.915 $ -3.09% 642,961
12/06/26 4.040 $ +3.32% 689,971
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
4.070USD
Average target price
10.44USD
Spread / Average Target
+156.45%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!